Mammalian haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof
View Patent ↗The invention relates to covalently cross-linked mammalian hemoglobins, to which polyalkylene oxides are covalently linked. Such hemoglobins are surprisingly compatible with proteins of human and animal plasma, under all the possible conditions within the vascular system of the body. The invention furthermore relates to the production of these cross-linked hemoglobins linked with polyalkylene oxides, as well as to their use as artificial intravasal oxygen carriers in the human or animal organism or in individual organs.
1. Hemoglobin derivative compatible with human and non-human animal plasma, comprising hemoglobin crosslinked by means of a crosslinker for proteins and a polyalkylene oxide covalently linked to the hemoglobin, with polyalkylene oxides being excluded as crosslinker and no reaction with diaspirin taking place, said crosslinker being a bifunctional crosslinker for proteins, selected from the group consisting of butane diepoxide, divinyl sulfone, a diisocyanate, a di-N-hydroxysuccinimidyl ester, a diimido ester and a dialdehyde.
2. Hemoglobin derivative compatible with plasma according to claim 1 , wherein the hemoglobin is of human origin, from the cow or from the pig.
3. Hemoglobin derivative compatible with plasma according to claim 1 , wherein a derivative of a polyalkylene oxide, selected from polyethylene oxide, polypropylene oxide or copolymers of ethylene oxide and propylene oxide is linked to the hemoglobin.
4. Hemoglobin derivative according to claim 3 , wherein between 1 and 40 molecules of polyalkylene oxide are linked per molecule of the hemoglobin monomer.
5. Hemoglobin derivative according to claim 1 , wherein the hemoglobin is crosslinked by means of glutaric dialdehyde.
6. Hemoglobin derivative according to claim 1 , wherein the crosslinked hemoglobin has molecular weights up to 10,000,000 g/mol.
7. Method for the preparation of hemoglobin derivatives as synthetic oxygen carriers which are compatible with human and non-human animal blood plasma, comprising crosslinking the hemoglobin with a crosslinker for proteins and covalently linking a polyalkylene oxide to the hemoglobin, the crosslinked hemoglobin having a molecular weight from 50,000 to 10,000,000 g/mol, polyalkylene oxides as crosslinkers being excluded and no reaction with diaspirin takes place.
8. Method according to claim 7 , characterized either
(i) first polyalkylene oxide is covalently linked to hemoglobin and this hemoglobin linked to polyalkylene oxide is then crosslinked, or
(ii) first the hemoglobin is crosslinked and then polyalkylene oxide is linked covalently to the crosslinked hemoglobin, or
(iii) first polyalkylene oxide is covalently linked to hemoglobin, this hemoglobin linked to polyalkylene oxide is then crosslinked, and to this hemoglobin linked to polyalkylene oxide and crosslinked, polyalkylene oxide is again covalently linked.
9. Method according to claim 7 , wherein the hemoglobins is from humans, cattle or pigs.
10. Method according to claim 7 , wherein hemoglobin in an aqueous electrolyte solution is crosslinked with a 3 to 60 times molar excess, with respect to monomeric hemoglobin, of a bifunctional crosslinker for proteins, and covalently linked with a 1 to 40 times molar excess, with respect to monomeric hemoglobin, of a polyalkylene oxide, and then the excess of the reactants is removed and the product is purified.
11. Method according to claim 10 , wherein the bifunctional crosslinker for proteins is selected from butane diepoxide, divylsulfone, a diisocyanate, a di-N-hydroxysuccinimidyl ester, a diimido ester and a dialdehyde.
12. Method according to claim 11 , wherein the bifunctional crosslinker for proteins is glutaric dialdehyde.
13. Method according to claim 7 , wherein a derivative of a polyethylene oxide, polypropylene oxide, or copolymers of ethylene oxide and propylene oxide is used as polyalkylene oxide.
14. Method of using a crosslinked hemoglobin compatible with plasma according to claim 1 , for intravascular or biomedical application as an artificial oxygen carriers, said method comprising administering said artificial oxygen carrier to a patient in need thereof.
15. Method according to claim 14 , which comprises administering the crosslinked hemoglobin to a patient in need thereof as a substitute for blood, or as an additive to blood, or in a nutrient solution.
16. Hemoglobin derivative according to claim 1 , wherein the diisocyanate is hexamethylene diisocyanate, cyclohexyl diisocyanate or 2,5-bisisocyanatobenzenesulfonic acid; or the dialdehyde is glyoxal, glycol aldehydes or glutaric dialdehyde.
17. Method according to claim 11 , wherein the diisocyanate is hexamethylene diisocyanate, cyclohexyl diisocyanate or 2,5-bisisocyanatobenzenesulfonic acid; or the dialdehyde is glyoxal, glycol aldehydes or glutaric dialdehyde.